With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Merck leans on Keytruda growth and pipeline expansion, Palo Alto rides subscription security demand, and Freeport benefits ...

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Merck was a detractor despite "solid" first-quarter results, as it "disappointed the market" with a more subdued outlook for the rest of the year as it trimmed earlier guidance amid a slowdown in ...

Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

Pyxis Oncology anticipates having preliminary data from the Phase 1/2 combination study of MICVO in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in R/M HNSCC and other ...

Alvotech ( (ALVO) ) has released its Q2 earnings. Here is a breakdown of the information Alvotech presented to its investors.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% ...

Q1 2026 Earnings Call Transcript August 13, 2025 Aethlon Medical, Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, expectations were $-0.68. Operator: Good afternoon, and welcome to ...